Skip to main content

Table 2 The number of pXDDIs, for which the CP recommended drug discontinuation

From: Evaluation of a collaborative care approach between general practitioners and clinical pharmacists in primary care community settings in elderly patients on polypharmacy in Slovenia: a cohort retrospective study reveals positive evidence for implementation

pXDDIs N prior N after pXDDIs N prior N after
 Amiodarone-torsemide 1 0 ipratropium / fenoterol-tiotropium 3 2
 Amiodarone-clozapine 1 0 quetiapine-amiodarone 1 0
 Amiodarone-warfarin 1 0 quetiapine -domperidone 2 1
 Etoricoxib-meloxicam 1 0 quetiapine -escitalopram 7 3
 Haloperidol-sulpiride 2 1 quetiapine-metoclopramide 3 2
 Haloperidol-metoclopramide 1 0 quetiapine-sulpiride 2 1
 Cholecalciferol-calcitriol 3 0 metoclopramide-trimetazidine 2 1
 Ipratropium/fenoterol-Olanzapine 2 1 sulpiride-risperidone 1 0
Not accepted pXDDIs N prior N after pXDDIs N prior N after
 Amisulpride-sulpiride 1 1 quetiapine-budenoside / formoterol 1 1
 Desloratadine-mirtazapine 1 1 quetiapine-domperidone 2 1
 Escitalopram-sotalol 1 1 quetiapine-escitalopram 7 3
 Haloperidol-sulpiride 2 1 quetiapine-haloperidol 3 3
 Haloperidol- ipratropium/phenoterol 1 1 quetiapine-metoclopramide 3 2
 Haloperidol ipratropium/phenoterol- 1 1 quetiapine-sulpiride 2 1
 Olanzapine- ipratropium/phenoterol 2 1 quetiapine-trazodone 1 1
 Quetiapine-tiotropium 1 1 quetiapine-tiotropium 1 1
 Carbamazepine-clozapine 3 2 metoclopramide-trimetazidine 2 1
 Carvedilol- budenoside/formoterol 2 2 olanzapine-thyrotropium 1 1
 Quetiapine- ipratropium/phenoterol 1 1 sulpiride-trimetazidine 1 1